| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Total revenues | 605,306 | 1,024,111 | 565,394 | 534,233.75* |
| Cost of product revenues | 158,184 | 197,325 | 250,037 | 324,507* |
| Gross profit | 447,122 | 826,786 | 315,357 | 209,726.75* |
| Selling, general and administrative | 2,139,964 | 2,591,647 | 13,348,510 | 2,717,147.5* |
| Realized gain on derivative written call options | 40,272 | 21,573 | - | - |
| Loss from change in fair value of digital assets | -502,687 | -2,086,347 | -1,732,557 | - |
| Loss from fair value measurement of investment in digital asset trust | -875,632 | -2,548,799 | -3,484,009 | - |
| Research and development | 209,830 | 372,149 | 458,562 | 1,504,228* |
| Total operating expenses | 3,687,841 | 7,577,369 | 19,023,638 | 4,221,375.5* |
| Loss from operations | -3,240,719 | -6,750,583 | -18,708,281 | -4,011,648.75* |
| Interest income | 793 | 3,761 | 9,143 | 48,228.75* |
| Unrealized gain on change in fair value of warrants classified as a liability | - | - | -370 | -79,907.5* |
| Other income (expense), net | - | 81,663 | 92,586 | -26,645* |
| Warrant inducement expense | 1,439,652 | - | - | - |
| Loss before provision for income taxes | -4,679,578 | -6,665,159 | -18,606,182 | -3,910,157.5* |
| Income tax provision benefit | - | - | - | -171,028.75* |
| Net loss from continuing operations | -4,679,578 | -6,665,159 | -18,606,182 | -3,739,128.75* |
| Clinical laboratory service revenues | - | - | - | 143,232* |
| Cost of clinical laboratory service revenues | - | - | - | 197,613.75* |
| Gross profit | - | - | - | -54,381.75* |
| Selling, general and administrative | - | - | - | 53,776.25* |
| Interest (income) | - | - | - | 825.25* |
| Other expense, net | - | - | - | 9,150* |
| Net loss from discontinued operations | - | - | - | -98,182.75 |
| Net loss from discontinued operations, net of tax | - | - | - | -98,182.75* |
| Net loss | -4,679,578 | -6,665,159 | -18,606,182 | -3,837,311.5* |
| Less net (income) loss attributable to noncontrolling interest | 6,727 | 68 | -12,619 | -47,130.5* |
| Net loss attributable to bnb plus corp | -4,686,305 | -6,665,227 | -18,593,563 | -3,790,181* |
| Deemed dividend related to warrant modifications | 43,944 | - | 32,827 | 13,581,724* |
| Cumulative dividends on series b-1 and b-2 preferred stock | 19,634 | - | - | - |
| Net loss attributable to common stockholders | -4,749,883 | -6,665,227 | -18,626,390 | -17,371,905 |
| Basic EPS | -0.57 | -0.68 | -2.08 | -33.558 |
| Diluted EPS | -0.57 | -0.68 | -2.08 | -33.558 |
| Basic Average Shares | 8,365,055 | 9,735,631 | 8,942,937 | 517,671 |
| Diluted Average Shares | 8,365,055 | 9,735,631 | 8,942,937 | 517,671 |
BNB PLUS CORP. (BNBX)
BNB PLUS CORP. (BNBX)